AACR 2021 – Affimed wins, Oncternal loses
Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.
Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Go or no go? The FDA plays hardball
April will see the US regulator examine Pfizer’s Jak in atopic dermatitis, and experts meet to discuss accelerated approvals in oncology.
Biotech’s important clinical data readouts
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
AACR 2021 preview – the early themes emerge
The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.
Wave gets another shot at Huntington’s
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
AD/PD 2021 – Donanemab has much still to prove
Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.
Lilly lines up its next shot at Alzheimer’s
Expectations are high ahead of a detailed look at donanemab data, but hopes for a fast path to market feel overblown.
